Skip to content
Valbenazine
Ingrezza (valbenazine) is a small molecule pharmaceutical. Valbenazine was first approved as Ingrezza on 2017-04-11. It is used to treat tardive dyskinesia in the USA. The pharmaceutical is active against synaptic vesicular amine transporter.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Ingrezza
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Valbenazine tosylate
Tradename
Company
Number
Date
Products
INGREZZANeurocrine BiosciencesN-209241 RX2017-04-11
3 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
ingrezzaNew Drug Application2020-04-09
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
tardive dyskinesia—D000071057G24.01
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Valbenazine Tosylate, Ingrezza, Neurocrine
109401412040-08-10U-1995
110269312039-08-14U-1995
110269392038-09-18DPU-1995
113115322038-09-18DPU-1995
108571372037-10-10U-1995
108571482037-10-10U-1995
108746482037-10-10U-1995, U-3046
109127712037-10-10U-1995, U-3076
109529972037-10-10U-1995
109939412037-10-10U-1995
110400292037-10-10U-1995
109069022036-12-22DS, DP
109069032036-12-22DS, DP
109198922036-12-22DS, DP
100659522036-10-28DS, DPU-1995
108440582036-10-28DS, DPU-1995
108511032036-10-28DS, DPU-1995
108511042036-10-28DPU-1995
80396272031-04-11DS, DP
83576972027-11-08U-1995
ATC Codes
N: Nervous system drugs
— N07: Other nervous system drugs in atc
— N07X: Other nervous system drugs in atc
— N07XX: Other nervous system drugs in atc
— N07XX13: Valbenazine
HCPCS
No data
Clinical
Clinical Trials
120 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Herpes simplexD006561B008463728
Hiv infectionsD015658EFO_0000764B201253617
Herpes genitalisD006558EFO_0007282A60—425415
Herpes zosterD006562EFO_0006510B021521413
Cytomegalovirus infectionsD003586EFO_0001062B25—112—4
SchizophreniaD012559EFO_0000692F20—3—1—4
Psychotic disordersD011618F20.81—3—1—4
Bell palsyD020330EFO_0007167G51.0———123
Varicella zoster virus infectionD0000736181——113
InfectionsD007239EFO_00005441——1—2
Show 7 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic neoplasmsD011471C61131——4
ChickenpoxD002644EFO_0007204B011—1—13
HivD006678O98.7——1—23
NeoplasmsD009369C80—11——2
Postherpetic neuralgiaD051474—11——2
Sexually transmitted diseasesD012749A50-A64——2——2
EncephalitisD004660——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GliomaD005910EFO_000052031———4
Non-small-cell lung carcinomaD002289—2———2
LeukemiaD007938C95—2———2
Epstein-barr virus infectionsD020031EFO_0000769—2———2
Cognitive dysfunctionD060825G31.84—2———2
Alzheimer diseaseD000544EFO_0000249F03—2———2
Chronic hepatitis bD019694EFO_0004197B18.111———2
GlioblastomaD005909EFO_000051511———2
AstrocytomaD001254EFO_000027111———2
Waldenstrom macroglobulinemiaD008258C88.0—1———1
Show 11 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—8———210
Lung neoplasmsD008175C34.902————2
Breast neoplasmsD001943EFO_0003869C501————1
Ovarian neoplasmsD010051EFO_0003893C561————1
MesotheliomaD008654C451————1
Malignant pleural effusionD016066J91.01————1
Hepatitis bD0065091————1
Pancreatic neoplasmsD010190EFO_0003860C251————1
EpendymomaD0048061————1
Bone marrow transplantationD0160261————1
Show 4 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acne vulgarisD000152EFO_0003894L70————11
Bacterial vaginosisD016585EFO_0003932————11
Immunologic deficiency syndromesD007153HP_0002721D84.9————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVALBENAZINE
INNvalbenazine
Description
Valbenazine, sold under the trade name Ingrezza, is a medication used to treat tardive dyskinesia. It acts as a vesicular monoamine transporter 2 (VMAT2) inhibitor.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1cc2c(cc1OC)[C@H]1C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CC2
Identifiers
PDB—
CAS-ID1025504-45-3
RxCUI1918219
ChEMBL IDCHEMBL2364639
ChEBI ID—
PubChem CID24795069
DrugBankDB11915
UNII ID54K37P50KH (ChemIDplus, GSRS)
Target
Agency Approved
SLC18A2
SLC18A2
Organism
Homo sapiens
Gene name
SLC18A2
Gene synonyms
SVMT, VMAT2
NCBI Gene ID
6571
Protein name
synaptic vesicular amine transporter
Protein synonyms
monoamine neurotransmitter transporter, Monoamine transporter, solute carrier family 18 (vesicular monoamine transporter), member 2, Solute carrier family 18 member 2, synaptic vesicle amine transporter, brain, synaptic vesicle monoamine transporter, brain, VAT2, vesicle monoamine transporter type 2, vesicle monoamine/H+ antiporter, Vesicular amine transporter 2
Uniprot ID
Q9H3P6
Mouse ortholog
Slc18a2 (214084)
synaptic vesicular amine transporter (Q8CC55)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 220 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
16,548 adverse events reported
View more details